This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A.
Specific Aims (for pilot projects): + To identify outstanding immunologic scientific opportunities for junior investigators + To provide start-up funds for previous COBRE investigators to generate additional preliminary data to apply for alternative funding sources. B. Studies and Results: We identified an opportunity to assist in the funding for the development of an additional core facility. After discussing thoroughly with the EAC, a human antibody core was created. Below describes the specific activities of the newly created Human Antibody Core, which was led by Dr. Patrick Wilson, until his departure in early summer 2008. Dr. Wilson was instrumental in the development of this new technology. However, the core key personnel have remained and Dr. Linda Thompson has assumed leadership of this core with the assistance of Dr. Kenneth Smith who was the co-first author on the initial manuscript describing this methodology (Nature 2008) as well as the recent publication in Nature Protocols describing this methodology. Through the development of this core, we can not only provide our COBRE investigators with an exciting new technology but also provide these investigators access to leading expertise in this area.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Exploratory Grants (P20)
Project #
5P20RR015577-10
Application #
7959382
Study Section
Special Emphasis Panel (ZRR1-RI-8 (01))
Project Start
2009-03-01
Project End
2010-02-28
Budget Start
2009-03-01
Budget End
2010-02-28
Support Year
10
Fiscal Year
2009
Total Cost
$136,166
Indirect Cost
Name
Oklahoma Medical Research Foundation
Department
Type
DUNS #
077333797
City
Oklahoma City
State
OK
Country
United States
Zip Code
73104
Hu, Zihua; Jiang, Kaiyu; Frank, Mark Barton et al. (2018) Modeling Transcriptional Rewiring in Neutrophils Through the Course of Treated Juvenile Idiopathic Arthritis. Sci Rep 8:7805
Hu, Zihua; Jiang, Kaiyu; Frank, Mark Barton et al. (2016) Complexity and Specificity of the Neutrophil Transcriptomes in Juvenile Idiopathic Arthritis. Sci Rep 6:27453
Molineros, Julio E; Maiti, Amit K; Sun, Celi et al. (2013) Admixture mapping in lupus identifies multiple functional variants within IFIH1 associated with apoptosis, inflammation, and autoantibody production. PLoS Genet 9:e1003222
Smith, Kenneth; Muther, Jennifer J; Duke, Angie L et al. (2013) Fully human monoclonal antibodies from antibody secreting cells after vaccination with Pneumovax®23 are serotype specific and facilitate opsonophagocytosis. Immunobiology 218:745-54
Dozmorov, Igor; Dominguez, Nicolas; Sestak, Andrea L et al. (2013) Evidence of dynamically dysregulated gene expression pathways in hyperresponsive B cells from African American lupus patients. PLoS One 8:e71397
Jiang, Kaiyu; Frank, Mark; Chen, Yanmin et al. (2013) Genomic characterization of remission in juvenile idiopathic arthritis. Arthritis Res Ther 15:R100
Kurien, Biji T; D'Sousa, Anil; Bruner, Benjamin F et al. (2013) Prolidase deficiency breaks tolerance to lupus-associated antigens. Int J Rheum Dis 16:674-80
Lin, C P; Adrianto, I; Lessard, C J et al. (2012) Role of MYH9 and APOL1 in African and non-African populations with lupus nephritis. Genes Immun 13:232-8
Hughes, Travis; Adler, Adam; Kelly, Jennifer A et al. (2012) Evidence for gene-gene epistatic interactions among susceptibility loci for systemic lupus erythematosus. Arthritis Rheum 64:485-92
Vaughn, Samuel E; Kottyan, Leah C; Munroe, Melissa E et al. (2012) Genetic susceptibility to lupus: the biological basis of genetic risk found in B cell signaling pathways. J Leukoc Biol 92:577-91

Showing the most recent 10 out of 194 publications